Epstein-Barr Virus Antibody Response Patterns in Endemic and Nonendemic Cases of Nasopharyngeal Carcinoma.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 41077708.
- Also identified by DOI 10.1093/infdis/jiaf526.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epstein-Barr virus (EBV) causes most nasopharyngeal carcinoma (NPC), a malignancy endemic in certain regions, presenting with nonspecific symptoms and lacking a robust minimally invasive biomarker. To assess previously developed multiplex Luminex assay EBV antibody signatures in a nonendemic population, we analyzed and compared 98 NPC sera and 142 matched controls from the nonendemic Head and Neck 5000 clinical cohort against an endemic Taiwan case-control cohort. All models, except the 2-antibody IgA panel, performed similarly, achieving 90%-99% accuracy in identifying EBV-positive NPC. Our results showed that EBV antibody panels can accurately define EBV-positive NPC regardless of endemicity.
Medical subject headings
- Antibodies, Viral
- Nasopharyngeal Neoplasms
- Herpesvirus 4, Human
- Epstein-Barr Virus Infections